Takeda advances TAK-438 into Phase III studies for treatment of acid-related diseases.
M2 PHARMA-September 19, 2011-Takeda advances TAK-438 into Phase III studies for treatment of acid-related diseases(C)2011 M2 COMMUNICATIONS
19 September 2011 - Japanese Takeda Pharmaceutical Company Limited (TYO:4502) said last Friday it had advanced TAK-438 into Phase III studies in Japan for the treatment of patients with acid-related diseases such as reflux esophagitis.
TAK-438, originated by Takeda, is a potassium-competitive acid blocker (P-CAB) that suppresses gastric acid secretion by inhibiting the binding of potassium ion (K+) to H+, K+-ATPase (proton pomp). It has a different mechanism of action from proton pump inhibitors (PPIs), the company added.
TAK-438 is anticipated to have, in clinical use, a more potent inhibitory effect on gastric acid secretion, a faster onset of action, and a longer lasting effect than PPIs, Takeda said.
The Phase III trials in Japan are multi-centric, and designed to assess the safety and efficacy of TAK-438 for diseases such as gastric ulcer, duodenal ulcer and reflux esophagitis.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 19, 2011|
|Previous Article:||Dynavax reports complete results from HEPLISAV Phase III study.|
|Next Article:||Trident begins Phase Ia study of HF1020.|